false--12-31Q12020truefalse0000059478P21D916160000091415000002240000023700000677500000
0000059478
2020-01-01
2020-03-31
0000059478
lly:A718NotesDueJune12025Member
2020-01-01
2020-03-31
0000059478
lly:A625Notesdue2031Member
2020-01-01
2020-03-31
0000059478
lly:A1.000NotesDueJune22022Member
2020-01-01
2020-03-31
0000059478
lly:A2.125NotesDueJune32030Member
2020-01-01
2020-03-31
0000059478
us-gaap:CommonClassAMember
2020-01-01
2020-03-31
0000059478
lly:A1.625NotesDueJune22026Member
2020-01-01
2020-03-31
0000059478
lly:A6.77NotesDueJanuary12036Member
2020-01-01
2020-03-31
0000059478
lly:A1.700Notesdue2049Member
2020-01-01
2020-03-31
0000059478
2020-04-27
0000059478
2019-01-01
2019-03-31
0000059478
us-gaap:SegmentContinuingOperationsMember
2020-01-01
2020-03-31
0000059478
us-gaap:SegmentContinuingOperationsMember
2019-01-01
2019-03-31
0000059478
us-gaap:SegmentDiscontinuedOperationsMember
2020-01-01
2020-03-31
0000059478
us-gaap:SegmentDiscontinuedOperationsMember
2019-01-01
2019-03-31
0000059478
2019-12-31
0000059478
2020-03-31
0000059478
2018-06-30
0000059478
us-gaap:TreasuryStockMember
2020-01-01
2020-03-31
0000059478
us-gaap:TreasuryStockMember
2020-03-31
0000059478
us-gaap:AdditionalPaidInCapitalMember
2019-01-01
2019-03-31
0000059478
us-gaap:CommonStockMember
2019-01-01
2019-03-31
0000059478
us-gaap:TrustForBenefitOfEmployeesMember
2018-12-31
0000059478
us-gaap:RetainedEarningsMember
2020-01-01
2020-03-31
0000059478
us-gaap:TreasuryStockMember
2018-12-31
0000059478
us-gaap:CommonStockMember
2020-01-01
2020-03-31
0000059478
us-gaap:TreasuryStockMember
2019-01-01
2019-03-31
0000059478
us-gaap:CommonStockMember
2019-03-31
0000059478
us-gaap:NoncontrollingInterestMember
2019-01-01
2019-03-31
0000059478
us-gaap:RetainedEarningsMember
2019-01-01
2019-03-31
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-12-31
0000059478
us-gaap:AdditionalPaidInCapitalMember
2019-03-31
0000059478
us-gaap:TreasuryStockMember
2019-12-31
0000059478
us-gaap:NoncontrollingInterestMember
2018-12-31
0000059478
us-gaap:CommonStockMember
2018-12-31
0000059478
us-gaap:TrustForBenefitOfEmployeesMember
2020-03-31
0000059478
us-gaap:CommonStockMember
2020-03-31
0000059478
us-gaap:RetainedEarningsMember
2018-12-31
0000059478
us-gaap:AdditionalPaidInCapitalMember
2020-01-01
2020-03-31
0000059478
us-gaap:AdditionalPaidInCapitalMember
2020-03-31
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2020-01-01
2020-03-31
0000059478
us-gaap:NoncontrollingInterestMember
2020-01-01
2020-03-31
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2020-03-31
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2018-12-31
0000059478
us-gaap:AdditionalPaidInCapitalMember
2018-12-31
0000059478
us-gaap:RetainedEarningsMember
2019-12-31
0000059478
us-gaap:CommonStockMember
2019-12-31
0000059478
us-gaap:NoncontrollingInterestMember
2019-03-31
0000059478
us-gaap:AdditionalPaidInCapitalMember
2019-12-31
0000059478
us-gaap:TrustForBenefitOfEmployeesMember
2019-12-31
0000059478
us-gaap:RetainedEarningsMember
2019-03-31
0000059478
us-gaap:NoncontrollingInterestMember
2019-12-31
0000059478
us-gaap:NoncontrollingInterestMember
2020-03-31
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-01-01
2019-03-31
0000059478
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2019-03-31
0000059478
us-gaap:TreasuryStockMember
2019-03-31
0000059478
us-gaap:RetainedEarningsMember
2020-03-31
0000059478
us-gaap:TrustForBenefitOfEmployeesMember
2019-03-31
0000059478
2018-12-31
0000059478
2019-03-31
0000059478
country:US
us-gaap:SalesReturnsAndAllowancesMember
2020-01-01
2020-03-31
0000059478
country:US
us-gaap:SalesReturnsAndAllowancesMember
2019-01-01
2019-03-31
0000059478
us-gaap:RoyaltyMember
2020-01-01
2020-03-31
0000059478
us-gaap:RoyaltyMember
2019-01-01
2019-03-31
0000059478
us-gaap:ProductMember
2020-01-01
2020-03-31
0000059478
us-gaap:ProductMember
2019-01-01
2019-03-31
0000059478
lly:CollaborationandOtherRevenueMember
2020-01-01
2020-03-31
0000059478
lly:CollaborationandOtherRevenueMember
2019-01-01
2019-03-31
0000059478
country:CN
2020-01-01
2020-03-31
0000059478
country:JP
2020-01-01
2020-03-31
0000059478
lly:OtherForeignCountriesMember
2019-01-01
2019-03-31
0000059478
srt:EuropeMember
2020-01-01
2020-03-31
0000059478
country:US
2020-01-01
2020-03-31
0000059478
country:US
2019-01-01
2019-03-31
0000059478
lly:OtherForeignCountriesMember
2020-01-01
2020-03-31
0000059478
srt:EuropeMember
2019-01-01
2019-03-31
0000059478
country:CN
2019-01-01
2019-03-31
0000059478
country:JP
2019-01-01
2019-03-31
0000059478
lly:OncologyMember
2020-01-01
2020-03-31
0000059478
lly:OtherNeuroscienceMember
country:US
2019-01-01
2019-03-31
0000059478
lly:ImmunologyMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:TaltzMember
2019-01-01
2019-03-31
0000059478
lly:TrulicityMemberMember
country:US
2019-01-01
2019-03-31
0000059478
lly:OtherNeuroscienceMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:DiabetesMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:ZyprexaMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:CialisMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:JardianceMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:CyramzaMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:CyramzaMember
2020-01-01
2020-03-31
0000059478
lly:OtherImmunologyMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:TaltzMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:HumalogMember
2020-01-01
2020-03-31
0000059478
lly:EmgalityMember
2020-01-01
2020-03-31
0000059478
lly:AlimtaMember
2019-01-01
2019-03-31
0000059478
lly:CialisMember
2020-01-01
2020-03-31
0000059478
lly:ZyprexaMember
country:US
2020-01-01
2020-03-31
0000059478
lly:OtherDiabetesMember
country:US
2019-01-01
2019-03-31
0000059478
lly:OtherImmunologyMember
2020-01-01
2020-03-31
0000059478
lly:NeuroscienceMember
country:US
2019-01-01
2019-03-31
0000059478
lly:AlimtaMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:VerzenioMember
2020-01-01
2020-03-31
0000059478
lly:EmgalityMember
2019-01-01
2019-03-31
0000059478
lly:ForteoMember
country:US
2020-01-01
2020-03-31
0000059478
lly:DiabetesMember
country:US
2019-01-01
2019-03-31
0000059478
lly:BasaglarMember
2020-01-01
2020-03-31
0000059478
lly:TrulicityMemberMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:HumalogMember
country:US
2019-01-01
2019-03-31
0000059478
lly:OtherProductMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:CymbaltaMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:HumulinMember
country:US
2020-01-01
2020-03-31
0000059478
lly:BasaglarMember
country:US
2019-01-01
2019-03-31
0000059478
lly:HumalogMember
country:US
2020-01-01
2020-03-31
0000059478
lly:CialisMember
2019-01-01
2019-03-31
0000059478
lly:OtherOncologyMember
2019-01-01
2019-03-31
0000059478
lly:VerzenioMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:JardianceMember
2020-01-01
2020-03-31
0000059478
lly:NeuroscienceMember
2019-01-01
2019-03-31
0000059478
lly:CymbaltaMember
2019-01-01
2019-03-31
0000059478
lly:AlimtaMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:EmgalityMember
country:US
2019-01-01
2019-03-31
0000059478
lly:CialisMember
country:US
2020-01-01
2020-03-31
0000059478
lly:ErbituxMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:OtherProductMember
2019-01-01
2019-03-31
0000059478
lly:OtherProductTotalMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:ErbituxMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:OlumiantMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:OtherOncologyMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:TrulicityMemberMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:OtherDiabetesMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:OtherDiabetesMember
country:US
2020-01-01
2020-03-31
0000059478
lly:OtherImmunologyMember
country:US
2020-01-01
2020-03-31
0000059478
lly:ZyprexaMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:ForteoMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:OlumiantMember
country:US
2019-01-01
2019-03-31
0000059478
lly:CymbaltaMember
country:US
2020-01-01
2020-03-31
0000059478
lly:EmgalityMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:OtherProductMember
2020-01-01
2020-03-31
0000059478
lly:OtherNeuroscienceMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:NeuroscienceMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:OncologyMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:ImmunologyMember
country:US
2020-01-01
2020-03-31
0000059478
lly:OncologyMember
country:US
2020-01-01
2020-03-31
0000059478
lly:OtherDiabetesMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:VerzenioMember
country:US
2019-01-01
2019-03-31
0000059478
lly:HumulinMember
country:US
2019-01-01
2019-03-31
0000059478
lly:CyramzaMember
country:US
2020-01-01
2020-03-31
0000059478
lly:JardianceMember
country:US
2019-01-01
2019-03-31
0000059478
lly:DiabetesMember
country:US
2020-01-01
2020-03-31
0000059478
lly:TaltzMember
2020-01-01
2020-03-31
0000059478
lly:OtherProductMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:OtherOncologyMember
2020-01-01
2020-03-31
0000059478
lly:HumalogMember
2019-01-01
2019-03-31
0000059478
lly:OtherProductMember
country:US
2020-01-01
2020-03-31
0000059478
lly:TaltzMember
country:US
2019-01-01
2019-03-31
0000059478
lly:TrajentaBIMember
2019-01-01
2019-03-31
0000059478
lly:TrulicityMemberMember
2019-01-01
2019-03-31
0000059478
lly:ZyprexaMember
2019-01-01
2019-03-31
0000059478
lly:TaltzMember
country:US
2020-01-01
2020-03-31
0000059478
lly:TrajentaBIMember
country:US
2019-01-01
2019-03-31
0000059478
lly:HumalogMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:OncologyMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:OtherOncologyMember
country:US
2019-01-01
2019-03-31
0000059478
lly:OtherProductTotalMember
2019-01-01
2019-03-31
0000059478
lly:TrulicityMemberMember
2020-01-01
2020-03-31
0000059478
lly:CymbaltaMember
country:US
2019-01-01
2019-03-31
0000059478
lly:OncologyMember
country:US
2019-01-01
2019-03-31
0000059478
lly:AlimtaMember
2020-01-01
2020-03-31
0000059478
lly:TrajentaBIMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:OtherDiabetesMember
2020-01-01
2020-03-31
0000059478
lly:ZyprexaMember
2020-01-01
2020-03-31
0000059478
lly:ImmunologyMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:OtherOncologyMember
country:US
2020-01-01
2020-03-31
0000059478
lly:ImmunologyMember
2020-01-01
2020-03-31
0000059478
lly:TrajentaBIMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:OtherImmunologyMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:OtherImmunologyMember
country:US
2019-01-01
2019-03-31
0000059478
lly:VerzenioMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:NeuroscienceMember
country:US
2020-01-01
2020-03-31
0000059478
lly:HumulinMember
2019-01-01
2019-03-31
0000059478
lly:OtherOncologyMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:NeuroscienceMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:OtherNeuroscienceMember
country:US
2020-01-01
2020-03-31
0000059478
lly:ForteoMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:ImmunologyMember
2019-01-01
2019-03-31
0000059478
lly:CymbaltaMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:BasaglarMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:OlumiantMember
2019-01-01
2019-03-31
0000059478
lly:BasaglarMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:CyramzaMember
2019-01-01
2019-03-31
0000059478
lly:ErbituxMember
country:US
2020-01-01
2020-03-31
0000059478
lly:TaltzMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:OncologyMember
2019-01-01
2019-03-31
0000059478
lly:AlimtaMember
country:US
2019-01-01
2019-03-31
0000059478
lly:DiabetesMember
2020-01-01
2020-03-31
0000059478
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:EmgalityMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:OtherProductTotalMember
country:US
2019-01-01
2019-03-31
0000059478
lly:CyramzaMember
country:US
2019-01-01
2019-03-31
0000059478
lly:CialisMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:AlimtaMember
country:US
2020-01-01
2020-03-31
0000059478
lly:HumalogMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:JardianceMember
2019-01-01
2019-03-31
0000059478
lly:TrajentaBIMember
country:US
2020-01-01
2020-03-31
0000059478
lly:OtherDiabetesMember
2019-01-01
2019-03-31
0000059478
lly:TrajentaBIMember
2020-01-01
2020-03-31
0000059478
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:BasaglarMember
country:US
2020-01-01
2020-03-31
0000059478
lly:OtherNeuroscienceMember
2020-01-01
2020-03-31
0000059478
lly:ForteoMember
2019-01-01
2019-03-31
0000059478
lly:BasaglarMember
2019-01-01
2019-03-31
0000059478
lly:OtherProductTotalMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:ErbituxMember
2020-01-01
2020-03-31
0000059478
lly:EmgalityMember
country:US
2020-01-01
2020-03-31
0000059478
lly:ForteoMember
country:US
2019-01-01
2019-03-31
0000059478
lly:TrulicityMemberMember
country:US
2020-01-01
2020-03-31
0000059478
lly:ErbituxMember
2019-01-01
2019-03-31
0000059478
lly:VerzenioMember
2019-01-01
2019-03-31
0000059478
lly:JardianceMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:OlumiantMember
2020-01-01
2020-03-31
0000059478
lly:CyramzaMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:HumulinMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:DiabetesMember
2019-01-01
2019-03-31
0000059478
lly:OtherProductMember
country:US
2019-01-01
2019-03-31
0000059478
lly:HumulinMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:ZyprexaMember
country:US
2019-01-01
2019-03-31
0000059478
lly:VerzenioMember
country:US
2020-01-01
2020-03-31
0000059478
lly:HumulinMember
2020-01-01
2020-03-31
0000059478
lly:DiabetesMember
us-gaap:NonUsMember
2020-01-01
2020-03-31
0000059478
lly:CialisMember
country:US
2019-01-01
2019-03-31
0000059478
lly:OtherProductTotalMember
country:US
2020-01-01
2020-03-31
0000059478
lly:NeuroscienceMember
2020-01-01
2020-03-31
0000059478
lly:ErbituxMember
country:US
2019-01-01
2019-03-31
0000059478
lly:OtherImmunologyMember
2019-01-01
2019-03-31
0000059478
lly:OlumiantMember
country:US
2020-01-01
2020-03-31
0000059478
lly:OlumiantMember
us-gaap:NonUsMember
2019-01-01
2019-03-31
0000059478
lly:OtherNeuroscienceMember
2019-01-01
2019-03-31
0000059478
lly:ForteoMember
2020-01-01
2020-03-31
0000059478
lly:ImmunologyMember
country:US
2019-01-01
2019-03-31
0000059478
lly:OtherProductTotalMember
2020-01-01
2020-03-31
0000059478
lly:JardianceMember
country:US
2020-01-01
2020-03-31
0000059478
lly:CymbaltaMember
2020-01-01
2020-03-31
0000059478
lly:ACImmuneSAMember
2019-01-01
2019-01-31
0000059478
lly:ImmuNextInc.Member
2019-03-01
2019-03-31
0000059478
lly:SitryxTherapeuticsLimitedMember
2020-01-01
2020-03-31
0000059478
lly:LoxoOncologyInc.Member
2019-02-15
0000059478
lly:SelpercatinibLOXO292Member
lly:LoxoOncologyInc.Member
2019-02-15
0000059478
lly:LoxoOncologyInc.Member
2019-02-01
2019-02-28
0000059478
lly:LoxoOncologyInc.Member
us-gaap:ContractBasedIntangibleAssetsMember
2019-02-15
2019-02-15
0000059478
lly:ACImmuneSAMember
2019-09-01
2019-09-30
0000059478
lly:DermiraInc.Member
2020-03-01
2020-03-31
0000059478
lly:DermiraInc.Member
2020-02-29
0000059478
lly:AbCelleraBiologicsInc.Member
2020-03-31
0000059478
lly:DermiraInc.Member
2020-02-20
2020-02-20
0000059478
lly:LebrikizumabMember
2020-03-31
0000059478
lly:TanezumabMember
lly:MilestonePaymentsSalesBasedMember
2020-01-01
2020-03-31
0000059478
lly:RocheMember
lly:LebrikizumabMember
lly:MilestonePaymentsSalesBasedMember
2020-01-01
2020-03-31
0000059478
lly:OlumiantMember
lly:MilestonePaymentsSalesBasedMember
2020-01-01
2020-03-31
0000059478
lly:RocheMember
lly:LebrikizumabMember
lly:MilestonePaymentsDevelopmentAndRegulatoryMember
2020-01-01
2020-03-31
0000059478
lly:OlumiantMember
us-gaap:RoyaltyAgreementTermsMember
2020-01-01
2020-03-31
0000059478
lly:TanezumabMember
lly:MilestonePaymentsDevelopmentAndRegulatoryMember
2020-01-01
2020-03-31
0000059478
lly:LebrikizumabMember
lly:MilestonePaymentsDevelopmentAndRegulatoryMember
2020-01-01
2020-03-31
0000059478
lly:LebrikizumabMember
lly:MilestonePaymentsSalesBasedMember
2020-01-01
2020-03-31
0000059478
lly:OlumiantMember
lly:MilestonePaymentsDevelopmentAndRegulatoryMember
2020-01-01
2020-03-31
0000059478
lly:OlumiantMember
lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember
2020-01-01
2020-03-31
0000059478
lly:TrajentaBIMember
lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember
2020-01-01
2020-03-31
0000059478
lly:JardianceMember
lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember
2020-01-01
2020-03-31
0000059478
lly:BasaglarMember
lly:MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember
2020-01-01
2020-03-31
0000059478
us-gaap:DiscontinuedOperationsDisposedOfBySaleMember
lly:ElancoAnimalHealthIncorporatedMember
2019-03-11
2019-03-11
0000059478
lly:EliLillyAndCompanyMember
us-gaap:DiscontinuedOperationsDisposedOfBySaleMember
lly:ElancoAnimalHealthIncorporatedMember
2019-03-11
0000059478
us-gaap:DiscontinuedOperationsDisposedOfBySaleMember
lly:ElancoAnimalHealthIncorporatedMember
2020-01-01
2020-03-31
0000059478
lly:LoxoOncologyInc.Member
2020-01-01
2020-03-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-01-01
2020-03-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:NondesignatedMember
2020-01-01
2020-03-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-01-01
2020-03-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-01-01
2019-03-31
0000059478
lly:HedgedFixedRateDebtMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-01-01
2020-03-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-01-01
2019-03-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:NondesignatedMember
2019-01-01
2019-03-31
0000059478
lly:HedgedFixedRateDebtMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-01-01
2019-03-31
0000059478
lly:SwapU.S.DollarsToEuroMember
2020-03-31
0000059478
lly:BuyEuroSellUsDollarMember
2020-03-31
0000059478
lly:BuyUsDollarSellEuroMember
2020-03-31
0000059478
lly:BuyBritishPoundandSellUSDollarsMember
2020-03-31
0000059478
lly:SwapSwissFrancsToU.S.DollarsMember
2020-03-31
0000059478
lly:BuyUSdollarSellJapaneseYenMember
2020-03-31
0000059478
us-gaap:InterestRateSwapMember
us-gaap:CashFlowHedgingMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
lly:SwapU.S.DollarsToBritishPoundsMember
2020-03-31
0000059478
lly:ForeignCurrencyDenominatedDebtMember
2020-03-31
0000059478
lly:SeniorNotesDueApril2050Member
us-gaap:SeniorNotesMember
us-gaap:SubsequentEventMember
2020-04-30
0000059478
lly:ForeignCurrencyDenominatedDebtMember
2019-12-31
0000059478
lly:HedgedFixedRateDebtMember
2019-01-01
2019-03-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
2020-01-01
2020-03-31
0000059478
us-gaap:InterestRateSwapMember
2019-01-01
2019-03-31
0000059478
lly:HedgedFixedRateDebtMember
2020-01-01
2020-03-31
0000059478
us-gaap:InterestRateSwapMember
2020-01-01
2020-03-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
2019-01-01
2019-03-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2020-03-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2020-03-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
2020-03-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2019-12-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
2020-03-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:NondesignatedMember
2019-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:NondesignatedMember
2019-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:NondesignatedMember
2020-03-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:NondesignatedMember
2019-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:NondesignatedMember
2020-03-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:NondesignatedMember
2020-03-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:NondesignatedMember
2020-03-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:NondesignatedMember
2019-12-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:NondesignatedMember
2019-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:ForeignExchangeContractMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:NondesignatedMember
2020-03-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:NetInvestmentHedgingMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:FairValueHedgingMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:InterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2019-12-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:CrossCurrencyInterestRateContractMember
us-gaap:CashFlowHedgingMember
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:DesignatedAsHedgingInstrumentMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2019-12-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
lly:EquityMethodAndOtherInvestmentsMember
2020-03-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2019-12-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2019-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2020-03-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2019-12-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2020-03-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2020-03-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2020-03-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
lly:MarketableSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2020-03-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2020-03-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2019-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2020-03-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2019-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
lly:MarketableSecuritiesMember
2019-12-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
2020-03-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2020-03-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2019-12-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2019-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2019-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2019-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2019-12-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:CarryingReportedAmountFairValueDisclosureMember
lly:EquityMethodAndOtherInvestmentsMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:CorporateDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:MarketableSecuritiesMember
2020-03-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel2Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:USGovernmentAgenciesDebtSecuritiesMember
2020-03-31
0000059478
us-gaap:FairValueInputsLevel3Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:MortgageBackedSecuritiesMember
2020-03-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2019-12-31
0000059478
us-gaap:EstimateOfFairValueFairValueDisclosureMember
us-gaap:OtherDebtSecuritiesMember
2019-12-31
0000059478
us-gaap:FairValueInputsLevel1Member
us-gaap:EstimateOfFairValueFairValueDisclosureMember
lly:OtherEquitySecuritiesMember
2019-12-31
0000059478
us-gaap:PortionAtOtherThanFairValueFairValueDisclosureMember
us-gaap:AssetBackedSecuritiesMember
2019-12-31
0000059478
us-gaap:PensionPlansDefinedBenefitMember
2020-01-01
2020-03-31
0000059478
us-gaap:PensionPlansDefinedBenefitMember
2019-01-01
2019-03-31
0000059478
us-gaap:SubsequentEventMember
2020-04-01
2020-04-30
0000059478
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2020-01-01
2020-03-31
0000059478
us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember
2019-01-01
2019-03-31
0000059478
lly:JapaneseAdministrativeProceedingsMember
2020-03-31
0000059478
lly:EmployeeLitigationMember
country:BR
2014-05-01
2014-05-31
0000059478
lly:EmgalityPatentLitigationMember
2020-02-29
0000059478
lly:DrReddysLabMember
2018-06-01
2018-06-30
0000059478
lly:InsulinPricingLitigationAndProceedingsHouseOfRepresentativesCommitteeOnEnergyAndCommerceMember
2020-03-31
0000059478
lly:EmployeeLitigationMember
country:BR
2019-07-01
2019-07-31
0000059478
lly:EmployeeLitigationMember
country:BR
2018-07-01
2018-07-31
0000059478
lly:EmgalityPatentLitigationMember
srt:ScenarioForecastMember
2020-04-01
2020-06-30
0000059478
lly:EmgalityPatentLitigationMember
2020-02-01
2020-02-19
0000059478
lly:EmployeeLitigationMember
country:BR
2020-03-31
2020-03-31
0000059478
lly:EmployeeLitigationMember
country:BR
2020-01-01
2020-03-31
0000059478
lly:DrReddysLabMember
2020-03-31
0000059478
lly:EmgalityPatentLitigationMember
2020-03-31
0000059478
lly:DrReddysLabMember
2019-12-01
2019-12-31
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2019-01-01
2019-03-31
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2020-01-01
2020-03-31
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2019-01-01
2019-03-31
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2019-01-01
2019-03-31
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
2020-01-01
2020-03-31
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
2019-01-01
2019-03-31
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2020-01-01
2020-03-31
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2020-01-01
2020-03-31
0000059478
us-gaap:AociAttributableToNoncontrollingInterestMember
2018-12-31
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember
2020-01-01
2020-03-31
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2019-01-01
2019-03-31
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2019-01-01
2019-03-31
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
2020-01-01
2020-03-31
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember
2019-01-01
2019-03-31
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
2020-01-01
2020-03-31
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceIncludingPortionAttributableToNoncontrollingInterestMember
2020-01-01
2020-03-31
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
2019-01-01
2019-03-31
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
lly:AccumulatedNetGainLossfromCashFlowHedgesandForeignCurrencyAdjustmentIncludingPortionAttributabletoNoncontrollingInterestMember
2019-01-01
2019-03-31
0000059478
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember
2020-01-01
2020-03-31
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-01-01
2019-03-31
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-01-01
2019-03-31
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-01-01
2019-03-31
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-12-31
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2018-12-31
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-01-01
2019-03-31
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-03-31
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2019-01-01
2019-03-31
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2019-03-31
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2018-12-31
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-12-31
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-12-31
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2018-12-31
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-03-31
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2019-03-31
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-03-31
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-03-31
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2020-01-01
2020-03-31
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2020-01-01
2020-03-31
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-12-31
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2020-01-01
2020-03-31
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2020-03-31
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2020-01-01
2020-03-31
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2020-01-01
2020-03-31
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-12-31
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-12-31
0000059478
us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2020-03-31
0000059478
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2019-12-31
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2020-03-31
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2019-12-31
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
2019-12-31
0000059478
us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2020-03-31
0000059478
us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentDiscontinuedOperationsMember
2020-03-31
0000059478
us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember
us-gaap:SegmentContinuingOperationsMember
2020-03-31
iso4217:EUR
iso4217:GBP
iso4217:USD
xbrli:pure
xbrli:shares
iso4217:JPY
iso4217:USD
xbrli:shares
iso4217:BRL
lly:case
lly:request
lly:patent
lly:lawsuit
lly:demand
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
Quarterly Report Under Section 13 or 15(d) of the
Securities Exchange Act of 1934
For the quarterly period ended March 31, 2020
COMMISSION FILE NUMBER 001-6351
ELI LILLY AND COMPANY
(Exact name of Registrant as specified in its charter)
|
| | |
Indiana | | 35-0470950 |
(State or other jurisdiction of | | (I.R.S. Employer |
incorporation or organization) | | Identification No.) |
Lilly Corporate Center, Indianapolis, Indiana 46285
(Address of principal executive offices)
Registrant’s telephone number, including area code (317) 276-2000
Securities registered pursuant to Section 12(b) of the Exchange Act: |
| | |
Title of Each Class | Trading Symbol | Name of Each Exchange On Which Registered |
Common Stock (no par value) | LLY | New York Stock Exchange |
1.000% Notes due 2022 | LLY22 | New York Stock Exchange |
7 1/8% Notes due 2025 | LLY25 | New York Stock Exchange |
1.625% Notes due 2026 | LLY26 | New York Stock Exchange |
2.125% Notes due 2030 | LLY30 | New York Stock Exchange |
0.625% Notes due 2031 | LLY31 | New York Stock Exchange |
6.77% Notes due 2036 | LLY36 | New York Stock Exchange |
1.700% Notes due 2049 | LLY49A | New York Stock Exchange |
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes ☒ No ☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of a “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
|
| | | | | | | |
Large accelerated filer | ☒ | | | | | Accelerated filer | ☐ |
Non-accelerated filer | ☐ | | | Smaller reporting company | ☐ |
| | | | | | Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
The number of shares of common stock outstanding as of April 27, 2020:
|
| | | |
Class | | Number of Shares Outstanding |
Common | | 956,450,448 |
|
Eli Lilly and Company
Form 10-Q
For the Quarter Ended March 31, 2020
Table of Contents
Forward-Looking Statements
This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “intend,” “anticipate,” “plan,” “continue,” or similar expressions.
In particular, information appearing under “Management's Discussion and Analysis of Results of Operations and Financial Condition” includes forward-looking statements. Forward-looking statements inherently involve many risks and uncertainties that could cause actual results to differ materially from those projected in these statements. Where, in any forward-looking statement, we (Lilly or the Company) express an expectation or belief as to future results or events, it is based on management's current plans and expectations, expressed in good faith and believed to have a reasonable basis. However, we can give no assurance that any such expectation or belief will result or will be achieved or accomplished. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated:
| |
• | uncertainties in the pharmaceutical research and development process, including with respect to the timing of anticipated regulatory approvals and launches of new products; |
| |
• | market uptake of recently launched products; |
| |
• | competitive developments affecting current products and our pipeline; |
| |
• | the expiration of intellectual property protection for certain of our products; |
| |
• | our ability to protect and enforce patents and other intellectual property; |
| |
• | the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals; |
| |
• | regulatory compliance problems or government investigations; |
| |
• | regulatory actions regarding currently marketed products; |
| |
• | unexpected safety or efficacy concerns associated with our products; |
| |
• | issues with product supply stemming from manufacturing difficulties or disruptions; |
| |
• | regulatory changes or other developments; |
| |
• | changes in patent law or regulations related to data-package exclusivity; |
| |
• | litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured; |
| |
• | unauthorized disclosure, misappropriation, or compromise of trade secrets or other confidential data stored in our information systems, networks, and facilities, or those of third parties with whom we share our data; |
| |
• | changes in tax law, including the impact of United States tax reform legislation enacted in December 2017 and related guidance, or events that differ from our assumptions related to tax positions; |
| |
• | changes in foreign currency exchange rates, interest rates, and inflation; |
| |
• | asset impairments and restructuring charges; |
| |
• | changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); |
| |
• | acquisitions and business development transactions and related integration costs; |
| |
• | information technology system inadequacies or operating failures; |
| |
• | the impact of the evolving COVID-19 pandemic and the global response thereto; |
| |
• | reliance on third-party relationships and outsourcing arrangements; and |
| |
• | the impact of global macroeconomic conditions. |
More information on factors that could cause actual results or events to differ materially from those anticipated is included from time to time in our reports filed with the SEC, including in Part II, Item 1A of this Form 10-Q and in our Annual Report on Form 10-K for the year ended December 31, 2019, particularly under the caption “Risk Factors”. All forward-looking statements speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this report. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this report.
PART I. Financial Information
Item 1. Financial Statements
Consolidated Condensed Statements of Operations
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars and shares in millions, except per-share data)
|
| | | | | | | |
| Three Months Ended March 31, |
| 2020 | | 2019 |
Revenue (Note 2) | $ | 5,859.8 |
| | $ | 5,092.2 |
|
Costs, expenses, and other: | | | |
Cost of sales | 1,215.1 |
| | 1,138.7 |
|
Research and development | 1,392.1 |
| | 1,230.5 |
|
Marketing, selling, and administrative | 1,549.6 |
| | 1,517.1 |
|
Acquired in-process research and development (Note 3) | 52.3 |
| | 136.9 |
|
Asset impairment, restructuring, and other special charges (Note 6) | 59.9 |
| | 423.9 |
|
Other–net, (income) expense (Note 12) | (89.1 | ) | | (86.0 | ) |
| 4,179.9 |
|
| 4,361.1 |
|
Income before income taxes | 1,679.9 |
|
| 731.1 |
|
Income taxes (Note 8) | 223.4 |
| | 170.0 |
|
Net income from continuing operations | 1,456.5 |
| | 561.1 |
|
Net income from discontinued operations (Note 5) | — |
| | 3,680.5 |
|
Net income | $ | 1,456.5 |
|
| $ | 4,241.6 |
|
| | | |
Earnings per share: | | | |
Earnings from continuing operations - basic | $ | 1.60 |
| | $ | 0.57 |
|
Earnings from discontinued operations - basic | — |
| | 3.76 |
|
Earnings per share - basic | $ | 1.60 |
| | $ | 4.33 |
|
| | | |
Earnings from continuing operations - diluted | $ | 1.60 |
| | $ | 0.57 |
|
Earnings from discontinued operations - diluted | — |
| | 3.74 |
|
Earnings per share - diluted | $ | 1.60 |
| | $ | 4.31 |
|
| | | |
Shares used in calculation of earnings per share: | | | |
Basic | 908.2 |
| | 979.9 |
|
Diluted | 911.7 |
| | 984.0 |
|
See notes to consolidated condensed financial statements.
Consolidated Condensed Statements of Comprehensive Income (Loss)
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)
|
| | | | | | | |
| Three Months Ended March 31, |
| 2020 | | 2019 |
Net income | $ | 1,456.5 |
| | $ | 4,241.6 |
|
Other comprehensive loss from continuing operations, net of tax (Note 11) | (362.3 | ) | | (4.1 | ) |
Other comprehensive income from discontinued operations, net of tax (Note 11) | — |
| | 56.8 |
|
Other comprehensive income (loss), net of tax (Note 11) | (362.3 | ) | | 52.7 |
|
Comprehensive income | $ | 1,094.2 |
|
| $ | 4,294.3 |
|
See notes to consolidated condensed financial statements.
Consolidated Condensed Balance Sheets
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)
|
| | | | | | | |
| March 31, 2020 | | December 31, 2019 |
Assets | (Unaudited) | | |
Current Assets | | | |
Cash and cash equivalents (Note 7) | $ | 1,699.0 |
| | $ | 2,337.5 |
|
Short-term investments (Note 7) | 78.4 |
| | 101.0 |
|
Accounts receivable, net of allowances of $23.7 (2020) and $22.4 (2019) | 5,106.1 |
| | 4,547.3 |
|
Other receivables | 1,246.4 |
| | 994.2 |
|
Inventories | 3,102.4 |
| | 3,190.7 |
|
Prepaid expenses and other | 2,761.9 |
| | 2,538.9 |
|
Total current assets | 13,994.2 |
| | 13,709.6 |
|
Investments (Note 7) | 2,148.7 |
| | 1,962.4 |
|
Goodwill | 3,779.1 |
| | 3,679.4 |
|
Other intangibles, net | 7,766.7 |
| | 6,618.0 |
|
Deferred tax assets | 2,471.6 |
| | 2,572.6 |
|
Property and equipment, net of accumulated depreciation of $9,141.5 (2020) and $9,161.6 (2019) | 7,897.9 |
| | 7,872.9 |
|
Other noncurrent assets | 3,044.6 |
| | 2,871.2 |
|
Total assets | $ | 41,102.8 |
|
| $ | 39,286.1 |
|
Liabilities and Equity | | | |
Current Liabilities | | | |
Short-term borrowings and current maturities of long-term debt | $ | 3,248.0 |
| | $ | 1,499.3 |
|
Accounts payable | 1,207.7 |
| | 1,405.3 |
|
Employee compensation | 565.8 |
| | 915.5 |
|
Sales rebates and discounts | 4,703.9 |
| | 4,933.6 |
|
Dividends payable | — |
| | 671.5 |
|
Income taxes payable | 667.4 |
| | 160.6 |
|
Other current liabilities | 2,217.4 |
| | 2,189.4 |
|
Total current liabilities | 12,610.2 |
| | 11,775.2 |
|
Other Liabilities | | | |
Long-term debt | 13,982.3 |
| | 13,817.9 |
|
Accrued retirement benefits (Note 9) | 3,632.0 |
| | 3,698.2 |
|
Long-term income taxes payable | 3,621.9 |
| | 3,607.2 |
|
Deferred tax liabilities | 2,186.2 |
| | 2,187.5 |
|
Other noncurrent liabilities | 1,873.0 |
| | 1,501.0 |
|
Total other liabilities | 25,295.4 |
| | 24,811.8 |
|
Commitments and Contingencies (Note 10) |
| |
|
Eli Lilly and Company Shareholders’ Equity | | | |
Common stock | 598.1 |
| | 598.8 |
|
Additional paid-in capital | 6,556.1 |
| | 6,685.3 |
|
Retained earnings | 5,879.4 |
| | 4,920.4 |
|
Employee benefit trust | (3,013.2 | ) | | (3,013.2 | ) |
Accumulated other comprehensive loss (Note 11) | (6,885.9 | ) | | (6,523.6 | ) |
Cost of common stock in treasury | (55.7 | ) | | (60.8 | ) |
Total Eli Lilly and Company shareholders’ equity | 3,078.8 |
| | 2,606.9 |
|
Noncontrolling interests | 118.4 |
| | 92.2 |
|
Total equity | 3,197.2 |
| | 2,699.1 |
|
Total liabilities and equity | $ | 41,102.8 |
| | $ | 39,286.1 |
|
See notes to consolidated condensed financial statements.
Consolidated Condensed Statements of Equity
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Equity of Eli Lilly and Company Shareholders | | |
(Dollars in millions and shares in thousands) | Common Stock | | Additional Paid-in Capital | | Retained Earnings | | Employee Benefit Trust | | Accumulated Other Comprehensive Loss | | Common Stock in Treasury | | Noncontrolling Interests |
Shares | | Amount | Shares | | Amount |
Balance at January 1, 2019 | 1,057,639 |
| | $ | 661.0 |
| | $ | 6,583.6 |
| | $ | 11,395.9 |
| | $ | (3,013.2 | ) | | $ | (5,729.2 | ) | | 604 |
| | $ | (69.4 | ) | | $ | 1,080.4 |
|
Net income |
|
| |
|
| |
|
| | 4,241.6 |
| |
|
| |
|
| |
|
| |
|
| | 22.2 |
|
Other comprehensive income, net of tax |
|
| |
|
| |
|
| |
|
| |
|
| | 41.7 |
| |
|
| |
|
| | 11.0 |
|
Retirement of treasury shares | (89,197 | ) | | (55.7 | ) | |
|
| | (10,771.8 | ) | |
|
| |
|
| | (89,197 | ) | | 10,827.5 |
| |
|
|
Purchase of treasury shares |
|
| |
|
| | (700.0 | ) | |
|
| |
|
| |
|
| | 24,196 |
| | (2,800.0 | ) | |
|
|
Issuance of stock under employee stock plans, net | 2,921 |
| | 1.8 |
| | (202.8 | ) | |
|
| |
|
| |
|
| | (63 | ) | | 7.3 |
| |
|
|
Stock-based compensation |
|
| |
|
| | 75.8 |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
Acquisition of common stock in exchange offer |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | 65,001 |
| | (8,027.5 | ) | |
|
|
Deconsolidation of Elanco |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | (1,028.9 | ) |
Other |
|
| |
|
| |
|
| | 13.7 |
| |
|
| |
|
| |
|
| |
|
| |
|
|
Balance at March 31, 2019 | 971,363 |
| | $ | 607.1 |
| | $ | 5,756.6 |
| | $ | 4,879.4 |
| | $ | (3,013.2 | ) | | $ | (5,687.5 | ) | | 541 |
| | $ | (62.1 | ) | | $ | 84.7 |
|
| | | | | | | | | | | | | | | | | |
Balance at January 1, 2020 | 958,056 |
| | $ | 598.8 |
| | $ | 6,685.3 |
| | $ | 4,920.4 |
| | $ | (3,013.2 | ) | | $ | (6,523.6 | ) | | 530 |
| | $ | (60.8 | ) | | $ | 92.2 |
|
Net income |
|
| |
|
| |
|
| | 1,456.5 |
| |
|
| |
|
| |
|
| |
|
| | 26.2 |
|
Other comprehensive loss, net of tax |
|
| |
|
| |
|
| |
|
| |
|
| | (362.3 | ) | |
|
| |
|
| |
|
|
Retirement of treasury shares | (3,627 | ) | | (2.3 | ) | |
|
| | (497.7 | ) | |
|
| |
|
| | (3,627 | ) | | 500.0 |
| |
|
|
Purchase of treasury shares (1) |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| | 3,627 |
| | (500.0 | ) | |
|
|
Issuance of stock under employee stock plans, net | 2,500 |
| | 1.6 |
| | (201.0 | ) | |
|
| |
|
| |
|
| | (43 | ) | | 5.1 |
| |
|
|
Stock-based compensation |
|
| |
|
| | 71.8 |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
Other |
|
| |
|
| |
|
| | 0.2 |
| |
|
| |
|
| |
|
| |
|
| |
|
|
Balance at March 31, 2020 | 956,929 |
| | $ | 598.1 |
| | $ | 6,556.1 |
| | $ | 5,879.4 |
| | $ | (3,013.2 | ) | | $ | (6,885.9 | ) | | 487 |
| | $ | (55.7 | ) | | $ | 118.4 |
|
See notes to consolidated condensed financial statements.
Consolidated Condensed Statements of Cash Flows
(Unaudited)
ELI LILLY AND COMPANY AND SUBSIDIARIES
(Dollars in millions)
|
| | | | | | | |
| Three Months Ended March 31, |
| 2020 | | 2019 |
Cash Flows from Operating Activities | |
Net income | $ | 1,456.5 |
| | $ | 4,241.6 |
|
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: | | | |
Gain related to disposition of Elanco (Note 5) | — |
| | (3,680.5 | ) |
Depreciation and amortization | 273.6 |
| | 356.5 |
|
Change in deferred income taxes | 11.2 |
| | (72.4 | ) |
Stock-based compensation expense | 71.8 |
| | 75.8 |
|
Acquired in-process research and development (Note 3) | 52.3 |
| | 136.9 |
|
Other changes in operating assets and liabilities, net of acquisitions and divestitures | (1,408.1 | ) | | (714.3 | ) |
Other non-cash operating activities, net | (74.9 | ) | | (32.3 | ) |
Net Cash Provided by Operating Activities | 382.4 |
| | 311.3 |
|
Cash Flows from Investing Activities | | | |
Net purchases of property and equipment | (258.3 | ) | | (203.7 | ) |
Proceeds from sales and maturities of short-term investments | 36.8 |
| | 35.9 |
|
Purchases of short-term investments | — |
| | (33.7 | ) |
Proceeds from sales of noncurrent investments | 54.5 |
| | 83.6 |
|
Purchases of noncurrent investments | (83.0 | ) | | (60.6 | ) |
Cash paid for acquisitions, net of cash acquired (Note 3) | (849.3 | ) | | (6,917.7 | ) |
Purchases of in-process research and development | (13.0 | ) | | (196.9 | ) |
Other investing activities, net | 51.4 |
| | (385.6 | ) |
Net Cash Used for Investing Activities | (1,060.9 | ) | | (7,678.7 | ) |
Cash Flows from Financing Activities | | | |
Dividends paid | (671.3 | ) | | (637.2 | ) |
Net change in short-term borrowings | 1,748.7 |
| | 1,850.4 |
|
Proceeds from issuance of long-term debt | — |
| | 4,448.3 |
|
Repayments of long-term debt | (276.3 | ) | | (600.0 | ) |
Purchases of common stock | (500.0 | ) | | (3,500.0 | ) |
Other financing activities, net | (194.4 | ) | | (193.7 | ) |
Net Cash Provided by Financing Activities | 106.7 |
| | 1,367.8 |
|
Effect of exchange rate changes on cash and cash equivalents | (66.7 | ) | | 37.8 |
|
| | | |
Net decrease in cash and cash equivalents | (638.5 | ) | | (5,961.8 | ) |
Cash and cash equivalents at January 1 (2019 includes $677.5 of discontinued operations) | 2,337.5 |
| | 7,998.2 |
|
Cash and Cash Equivalents at March 31 | $ | 1,699.0 |
| | $ | 2,036.4 |
|
See notes to consolidated condensed financial statements.
Notes to Consolidated Condensed Financial Statements
(Tables present dollars in millions, except per-share data)
Note 1: Basis of Presentation
We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.
The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2019. We issue our financial statements by filing them with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing of our Form 10-Q. All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis, that is, based on the weighted-average number of outstanding common shares plus the effect of incremental shares from our stock-based compensation programs.
We operate as a single operating segment engaged in the discovery, development, manufacturing, marketing, and sales of pharmaceutical products worldwide. A global research and development organization and a supply chain organization are responsible for the discovery, development, manufacturing, and supply of our products. Regional commercial organizations market, distribute, and sell the products. The business is also supported by global corporate staff functions. Our determination that we operate as a single segment is consistent with the financial information regularly reviewed by the chief operating decision maker for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods.
Note 2: Revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations: |
| | | | | | | |
| Three Months Ended March 31, |
| 2020 | | 2019 |
Net product revenue | $ | 5,403.5 |
| | $ | 4,692.3 |
|
Collaboration and other revenue (1) | 456.3 |
| | 399.9 |
|
Revenue | $ | 5,859.8 |
| | $ | 5,092.2 |
|
(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $35.4 million and $35.5 million during the three months ended March 31, 2020 and 2019, respectively.
We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to certain of our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Trajenta® and Jardiance® families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.
Adjustments to Revenue
Adjustments to revenue recognized as a result of changes in estimates for our most significant U.S. sales returns, rebates, and discounts liability balances for products shipped in previous periods were approximately 2 percent and 3 percent of U.S. revenue during the three months ended March 31, 2020 and 2019, respectively.
Contract Liabilities
Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract.
The following table summarizes contract liability balances: |
| | | | | | | |
| March 31, 2020 | | December 31, 2019 |
Contract liabilities | $ | 307.8 |
| | $ | 264.6 |
|
During the three months ended March 31, 2020 and 2019, revenue recognized from contract liabilities as of the beginning of the year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.
Disaggregation of Revenue
The following table summarizes revenue by product:
|
| | | | | | | | | | | | | | | | | | | |
| Three Months Ended March 31, |
| 2020 | | 2019 |
| United States (U.S.) (1) | Outside U.S. | Total | | U.S. (1) | Outside U.S. | Total |
Revenue—to unaffiliated customers: | | | | | | | |
Diabetes: | | | | | | | |
Trulicity® | $ | 929.5 |
| $ | 299.9 |
| $ | 1,229.4 |
| | $ | 665.6 |
| $ | 214.1 |
| $ | 879.7 |
|
Humalog® (2) | 398.6 |
| 297.2 |
| 695.8 |
| | 448.6 |
| 282.2 |
| 730.8 |
|
Humulin® | 214.1 |
| 101.5 |
| 315.7 |
| | 201.3 |
| 96.4 |
| 297.7 |
|
Basaglar® | 230.4 |
| 73.3 |
| 303.7 |
| | 198.2 |
| 53.2 |
| 251.4 |
|
Jardiance (3) | 144.6 |
| 122.9 |
| 267.5 |
| | 125.2 |
| 78.4 |
| 203.6 |
|
Trajenta (4) | 28.7 |
| 64.5 |
| 93.2 |
| | 47.4 |
| 84.6 |
| 131.9 |
|
Other Diabetes | 45.3 |
| 18.4 |
| 63.6 |
| | 33.1 |
| 24.7 |
| 57.9 |
|
Total Diabetes | 1,991.2 |
| 977.7 |
| 2,968.9 |
| | 1,719.4 |
| 833.6 |
| 2,553.0 |
|
| | | | | | | |
Oncology: | | | | | | | |
Alimta® | 324.2 |
| 235.8 |
| 560.1 |
| | 281.8 |
| 217.4 |
| 499.2 |
|
Cyramza® | 89.1 |
| 149.9 |
| 239.0 |
| | 75.1 |
| 123.2 |
| 198.3 |
|
Verzenio® | 129.4 |
| 58.6 |
| 188.0 |
| | 93.5 |
| 15.9 |
| 109.4 |
|
Erbitux® | 117.8 |
| 13.0 |
| 130.8 |
| | 113.3 |
| 5.1 |
| 118.4 |
|
Other Oncology | (2.6 | ) | 86.3 |
| 83.6 |
| | 30.2 |
| 57.3 |
| 87.4 |
|
Total Oncology | 657.9 |
| 543.6 |
| 1,201.5 |
| | 593.9 |
| 418.9 |
| 1,012.7 |
|
| | | | | | | |
Immunology: | | | | | | | |
Taltz® | 327.5 |
| 116.0 |
| 443.5 |
| | 180.8 |
| 71.7 |
| 252.5 |
|
Olumiant® | 11.3 |
| 128.4 |
| 139.7 |
| | 6.4 |
| 75.7 |
| 82.1 |
|
Other Immunology | 2.6 |
| — |
| 2.6 |
| | — |
| — |
| — |
|
Total Immunology | 341.4 |
| 244.4 |
| 585.8 |
| | 187.2 |
| 147.4 |
| 334.7 |
|
| | | | | | | |
Neuroscience: | | | | | | | |
Cymbalta® | 11.6 |
| 198.8 |
| 210.4 |
| | 10.3 |
| 153.8 |
| 164.1 |
|
Zyprexa® | 11.2 |
| 87.2 |
| 98.4 |
| | 9.3 |
| 97.9 |
| 107.2 |
|
Emgality® | 67.3 |
| 6.7 |
| 74.0 |
| | 12.2 |
| 2.1 |
| 14.2 |
|
Other Neuroscience | 20.2 |
| 60.5 |
| 80.7 |
| | 19.3 |
| 88.2 |
| 107.6 |
|
Total Neuroscience | 110.3 |
| 353.2 |
| 463.5 |
| | 51.1 |
| 342.0 |
| 393.1 |
|
| | | | | | | |
Other: | | | | | | | |
Forteo® | 122.5 |
| 149.8 |
| 272.4 |
| | 125.9 |
| 187.0 |
| 312.9 |
|
Cialis® | 26.1 |
| 167.0 |
| 193.0 |
| | 143.2 |
|
|